Girentuximab
http://dbpedia.org/resource/Girentuximab an entity of type: Thing
جيرنتوكسيماب هو جسم مضاد وحيد النسيلة مجانس مصمم لعلاج طورته شركة اسمها Wilex AG. يستهدف هذا الضد مستقبل Carbonic anhydrase IX الذي يتم التعبير عنه على سطح الخلايا السرطانية الكلوية. يعرف المستقبل بالاختصار CA9/CA IX ويعبر عنه من خلال الجين CA9.
rdf:langString
Le girentuximab est un anticorps monoclonal chimérique utilisée dans le traitement du carcinome à cellules rénales (CCR).
rdf:langString
Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy. It triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.
rdf:langString
rdf:langString
جيرنتوكسيماب
rdf:langString
Girentuximab
rdf:langString
Girentuximab
xsd:integer
33025505
xsd:integer
1100018419
rdf:langString
none
xsd:integer
6460
xsd:integer
916138
rdf:langString
none
xsd:integer
10006
xsd:integer
1718
xsd:integer
2018
xsd:integer
48
rdf:langString
xi
rdf:langString
Rencarex
rdf:langString
mab
xsd:integer
539
rdf:langString
changed
xsd:integer
458274725
rdf:langString
changed
rdf:langString
جيرنتوكسيماب هو جسم مضاد وحيد النسيلة مجانس مصمم لعلاج طورته شركة اسمها Wilex AG. يستهدف هذا الضد مستقبل Carbonic anhydrase IX الذي يتم التعبير عنه على سطح الخلايا السرطانية الكلوية. يعرف المستقبل بالاختصار CA9/CA IX ويعبر عنه من خلال الجين CA9.
rdf:langString
Girentuximab (trade name Rencarex) is a chimeric IgG1 monoclonal antibody to carbonic anhydrase IX (CAIX). CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or unconjugated antibody during phase III trials due to efficacy. Girentuximab was originally developed by Wilex AG, Germany. It was granted fast track status and orphan drug designation by the FDA for renal cancer. In January 2017, Telix Pharmaceuticals Limited, an Australian biotechnology company, announced that it had in-licensed Girentuximab for use as a radioimmunoconjugate. It triggers antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.
rdf:langString
Le girentuximab est un anticorps monoclonal chimérique utilisée dans le traitement du carcinome à cellules rénales (CCR).
rdf:langString
mab
xsd:nonNegativeInteger
4109
rdf:langString
Rencarex
xsd:string
916138-87-9
xsd:string
539B57DFJF